Kissei Launches First Domestically Developed Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Kissei Pharmaceutical and Nippon Chemical Research announced May 26 the market launch of Epoetin Alpha BS JCR injection, the first domestically developed follow-on biologic in Japan